← All trials
NCT06257576
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 26, 2024
- Primary completion
- Feb 28, 2026
- Completion date
- Aug 31, 2026
- First posted
- Feb 14, 2024
- Last posted
- Mar 6, 2024
- Enrollment
- 212
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emory UniversityLead sponsor
- Emory UniversitySponsor investigator
- Emory UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.